An article about ArcticZymes’ collaboration with the cluster Biotech North, appears in the November 2015 issue of Mercur a publication by Oslo Chambre of Commerce.
ArcticZymes AS has received ISO certification for product development, sales and marketing, manufacturing and distribution of all our products.
The quality management system of ArcticZymes AS has been certified under the ISO 9001:2008 standard by Det Norske Veritas (DNV). The certificate is valid for 3 years.
The report “Nordkloden: Verdiskaping og ressurser. Klimaendringer og kunnskap. Utviklingen nord på kloden angår oss alle” was published by the Ministry of Foreign Affairs, November 2014. In this report, ArcticZymes collaboration with the University of Tromsø – The arctic university of Norway, is used as an example to show the important link between academic science and development of new industry. The university’s impact is discussed in the chapter: “Læring for livet. Forskning. Kunnskap. Innovasjon. Nøkkelfaktorer for fremtidig suksess – og et viktig premiss for regjeringens satsing i nord.” ArcticZymes is mentioned on pages 34-36 of the report.
Norway’s arctic policy
Report | Published: 2014-11-10
The report “Norway’s arctic policy: Creating value, managing resources, confronting climate change and fostering knowledge. Developments in the Arctic concern us all.” was presented by Prime Minister Erna Solberg and Minister of Foreign Affairs, Børge Brende in the city of Hammerfest 10 November 2014.
Read the report here (Norwegian only).
ArcticZymes AS has received a Notice of Allowance for the United States Patent Application No. 14/036459 further covering patentable subject matter of its heat-labile dsDNase product.
With the approval of the new patent in the USA, ArcticZymes strengthens its rapidly growing intellectual property portfolio. The patent extends protection in the USA to the nucleic acid sequence of the heat-labile dsDNase. This includes a method of isolation and purification of the expressed sequence and subsequent incorporation into kit based technologies. This complements earlier patent protection granted in 2013, which covers amongst others the dsDNase itself, methods for removing contaminations from a sample reaction, as well as kits or compositions comprising the dsDNase.
“This latest patent approval strengthens the overall commercial potential for the innovative HL-dsDNase product in the USA. Furthermore, it supports our commercial efforts with Business-to-business partners.” says Managing Director, Jethro Holter at ArcticZymes AS.
For additional information contact:
Jethro Holter, Managing Director, +47 46 85 91 46, firstname.lastname@example.org